# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN-TD
- Date: 1881-08-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Konrad Ellison-Mbatha, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review after starting galcanezumab and the butalbital taper. **S**

## History of present illness

Mr. Nietzsche returns four weeks after the consultation. He finished the taper eight days ago. In the first ten days of the taper his headaches were worse, with six days in a row of headache and vomiting on two, as he had been warned; since then they have eased. His diary shows 14 headache days in the past four weeks, 8 with migraine features, and only 2 headache days in the eight days since the last tablet. Apart from the scheduled taper doses he used acute medicine on 6 days: naproxen on 6, with metoclopramide on 3. He had no tremor, sweating, confusion or seizure; his sleep was worse for a few nights in the second week. The nurse phone check planned for the end of the first taper week did not take place. The first galcanezumab injection left a small red patch for a day. His constipation is no worse. The floaters in his right eye from two weeks ago are fading, with no new flashes. He has had contact lenses fitted and reads more comfortably with the left eye. He has had two CBT-I sessions and sleeps about five hours. **S**

| Element | Detail |
|---|---|
| Taper | Completed eight days ago; rebound headache in the first ten days; no withdrawal symptoms |
| Headache days | 14 in the past four weeks, 8 with migraine features; 2 in the last eight days |
| Acute medicine | Naproxen on 6 days, metoclopramide on 3, besides the taper doses |
| Galcanezumab | Mild redness at the first injection site; constipation unchanged |
| Eyes | Contact lenses fitted; floaters fading |
| Sleep | About five hours; two CBT-I sessions |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Fading floaters in the right eye; no new flashes or shadow |
| Gastrointestinal | Positive | Vomiting on two days early in the taper; constipation no worse |
| Neurological | Positive | Headaches as in the diary; no tremor, confusion or seizure |
| Psychiatric | Negative | Mood steady; no hopelessness or thoughts of self-harm |

4 systems reviewed. **S**

## Current medications

- Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week **S**
- Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week **S**
- Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention **S**
- Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a month **S**

## Allergies

- No known allergy **S**

## Objective

BP 114/72 mmHg; pulse 64 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 66.6 kg; BMI 22 kg/m². All vital signs are synthetic.

No condition-specific results recorded.

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 114/72, pulse 64 |
| Skin | First injection site on the abdomen healed |
| Neurological | No tremor; normal examination |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Medication overuse headache** (G44.40). Taper completed without withdrawal symptoms beyond the expected rebound headache, which is settling. The phone check planned for the end of the first week was missed. **S**
   - No butalbital or combination products from now on.
   - Count every acute-medicine day in the diary.
2. **Chronic migraine without aura on galcanezumab** (G43.709). Too early to judge prevention, since the withdrawal weeks are in the count; galcanezumab is well tolerated. No cardiovascular contraindication to a triptan: blood pressure 114/72, no chest pain, vascular disease or smoking. **S**
   - Second galcanezumab injection, 120 mg, today.
   - Add sumatriptan 100 mg early in an attack, no more than two days a week and eight days a month; naproxen and metoclopramide as before.
   - Eight-week review with the MIDAS, PHQ-9 and GAD-7.
3. **Chronic insomnia** (G47.00). About five hours of sleep after two CBT-I sessions. **S**
   - Continue CBT-I with a fixed rising time.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Red-flag screen (SNNOOP10): systemic signs, neurological signs, sudden onset, onset after 50, change in pattern, positional or Valsalva features, papilledema, progressive course | Every visit | Completed today | No red flags |
| Survey | Headache diary: headache days, migraine days, attack features, triggers | Every visit | Completed today | 14 headache days in four weeks, 8 with migraine features, including the withdrawal weeks; 2 in the last eight days |
| Medication safety | Acute-medicine days (overuse limits: combination analgesics, triptans fewer than 10 days a month, simple analgesics fewer than 15) | Every visit | Completed today | Naproxen on 6 days besides the scheduled taper doses; no butalbital since the taper ended |
| Medication safety | Barbiturate withdrawal: tremor, sweating, agitation, insomnia, confusion, seizures; rebound headache | During the three-week taper and at the first visit after it | Deferred | The nurse phone check planned for the end of the first taper week did not take place. No harm resulted: he had rebound headache only, with no tremor, sweating, confusion or seizure, and he finished the taper as written. Corrective action: phone checks during any future taper are booked at the visit that starts it |
| Medication safety | Galcanezumab tolerability: injection sites, constipation, blood pressure, hypersensitivity | Before starting and at each injection visit | Completed today | Mild redness at the first site for a day; constipation unchanged; blood pressure 114/72; second dose given today |
| Medication safety | Cardiovascular screen before a triptan | Before the first triptan prescription | Completed today | No chest pain, vascular disease, uncontrolled blood pressure or smoking; blood pressure 114/72 |
| Examination | Preventive efficacy (at least 50% fewer monthly migraine days; headache days below 15 a month) | At three months on treatment | Due | Four weeks on galcanezumab, including the withdrawal weeks; judged at about three months |
| Survey | Disability (MIDAS, recorded as its five items, and HIT-6) | At baseline and after two to three months of treatment | Due | Repeat at the eight-week review |
| Survey | Mood (PHQ-9) and anxiety (GAD-7), with direct questions about hopelessness and self-harm | At baseline and at two to three months; questions at every visit | Due | PHQ-9 and GAD-7 at the eight-week review; no hopelessness or thoughts of self-harm today |
| Examination | Dilated re-examination after an acute posterior vitreous detachment | Within six weeks of the detachment, sooner with new symptoms | Due | Detachment two weeks ago without a break; floaters fading; re-examination at the eight-week review |
| Examination | Contact lens fit and corrected vision | After fitting | Completed today | Lenses fitted; left eye 20/20 and right eye 20/100 with lenses |
| Self-management | Sleep: hours, sleep diary, insomnia severity; no sedative sleeping tablets | Every visit | Completed today | About five hours; two CBT-I sessions; no sleeping tablets |

## Goal progress

- A two-week headache diary and the tests that allow a firm diagnosis. Outcome by 1881-07-21: Diary of 14 days kept; ICHD-3 criteria for chronic migraine and medication overuse headache met; MRI normal; syphilis serology nonreactive. **S**
- Stop the butalbital combination safely. Outcome by 1881-08-18: Three-week taper completed a week before the four-week review; no withdrawal seizure or delirium; withdrawal headache settled within ten days. **S**
- Fewer than 15 headache days a month, and at least half as many migraine days, within three months of starting prevention. In progress; target 1881-10-13. **S**
- Acute medicine on no more than eight days a month after withdrawal. In progress; target 1881-09-15. **S**
- Clear vision in the left eye for reading and protection of the right eye. Outcome by 1881-08-18: Contact lenses fitted; left eye 20/20 and right eye 20/100 corrected; knows the warning signs of retinal detachment. **S**
- Six and a half hours of sleep on most nights without sleeping tablets. In progress; target 1881-10-13. **S**

## Medication changes

- Started: Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a month **S**

## Guideline basis

- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (2018), International Headache Society (Cephalalgia 2018;38(1):1-211)
- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update (2024), American Headache Society (Headache 2024;64(4):333-341)
- European Academy of Neurology guideline on the management of medication-overuse headache (2020), European Academy of Neurology (European Journal of Neurology 2020;27(7):1102-1116)
- European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update (2022), European Headache Federation (Journal of Headache and Pain 2022;23(1):67)
- Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question (2013), American Headache Society (Headache 2013;53(10):1651-1659)
- Refractive Errors Preferred Practice Pattern (2023), American Academy of Ophthalmology (Ophthalmology 2023;130(3):P1-P60)
- Posterior Vitreous Detachment, Retinal Breaks, and Lattice Degeneration Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025;132(4):P163-P196)
- Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline (2021), American Academy of Sleep Medicine (Journal of Clinical Sleep Medicine 2021;17(2):255-262)
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in two weeks. Eight-week review in four weeks with the third galcanezumab injection and the repeat dilated eye examination. Same-day eye care for new flashes, a shower of floaters or a shadow. **S**
- Next scheduled visit 1881-09-01: periodic adult preventive visit. **S**
